Literature DB >> 19629637

Suppressive effect of dexamethasone on TIMP-1 production involves murine osteoblastic MC3T3-E1 cell apoptosis.

Hui Xie1, Ling-Li Tang, Xiang-Hang Luo, Xi-Yu Wu, Xian-Ping Wu, Hou-De Zhou, Ling-Qing Yuan, Er-Yuan Liao.   

Abstract

High dose glucocorticoid (GC) treatment induces osteoporosis partly via increasing osteoblast apoptosis. However, the mechanism of GC-induced apoptosis has not been fully elucidated. Osteoblast-derived tissue inhibitor of metalloproteinase-1 (TIMP-1) was recently reported to be involved in bone metabolism. Our previous study demonstrated that TIMP-1 suppressed apoptosis of the mouse bone marrow stromal cell line MBA-1 (pre-osteoblast) induced by serum deprivation. Therefore, we tested the effect of the GC dexamethasone (Dex) on TIMP-1 production in murine osteoblastic MC3T3-E1 cells and further determined whether this action is associated with Dex-induced osteoblast apoptosis. Dex decreased TIMP-1 production in MC3T3-E1 cells, and this effect was blocked by the glucocorticoid receptor (GR) antagonists, RU486 and RU40555. Recombinant TIMP-1 protein reduced caspase-3 activation and apoptosis induced by Dex in MC3T3-E1 cells. In addition, the pro-apoptotic effect of the Dex was augmented by suppression of TIMP-1 with siRNA. Furthermore, mutant TIMP-1, which has no inhibitory effects on MMPs, yet protects MC3T3-E1 cells against Dex-induced apoptosis. Our study demonstrates that Dex suppresses TIMP-1 production in osteoblasts through GR, and this effect is associated with its induction of osteoblast apoptosis. The anti-apoptotic action of TIMP-1 is independent of its inhibitory effects on MMPs activities. The decrease in TIMP-1 production caused by Dex may contribute to the mechanisms of Dex-induced bone loss.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629637     DOI: 10.1007/s00726-009-0325-9

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  7 in total

1.  Role of tissue inhibitor of metalloproteinases-1 in the development of autoimmune lymphoproliferation.

Authors:  Elena Boggio; Manuela Indelicato; Elisabetta Orilieri; Riccardo Mesturini; Maria Clorinda Mazzarino; Maria Francesca Campagnoli; Ugo Ramenghi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  Haematologica       Date:  2010-06-30       Impact factor: 9.941

2.  Post-menopausal oestrogen deficiency induces osteoblast apoptosis via regulating HOTAIR/miRNA-138 signalling and suppressing TIMP1 expression.

Authors:  Shao-Yong Xu; Peng Shi; Rui-Ming Zhou
Journal:  J Cell Mol Med       Date:  2021-03-17       Impact factor: 5.310

3.  Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells.

Authors:  Hui Li; Wenwei Qian; Xisheng Weng; Zhihong Wu; Huihua Li; Qianyu Zhuang; Bin Feng; Yanyan Bian
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

4.  Puerarin attenuates glucocorticoid-induced apoptosis of hFOB1.19 cells through the JNK- and Akt-mediated mitochondrial apoptotic pathways.

Authors:  Dongdong Yu; Shuai Mu; Danyang Zhao; Guangbin Wang; Zhiguang Chen; Hongfei Ren; Qin Fu
Journal:  Int J Mol Med       Date:  2015-06-23       Impact factor: 4.101

5.  The osteogenesis-promoting effects of alpha-lipoic acid against glucocorticoid-induced osteoporosis through the NOX4, NF-kappaB, JNK and PI3K/AKT pathways.

Authors:  Shi-Yu Lu; Chang-Yuan Wang; Yue Jin; Qiang Meng; Qi Liu; Zhi-Hao Liu; Ke-Xin Liu; Hui-Jun Sun; Mo-Zhen Liu
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

6.  Haem oxygenase-1 induction prevents glucocorticoid-induced osteoblast apoptosis through activation of extracellular signal-regulated kinase1/2 signalling pathway.

Authors:  Qiaoli Gu; Mimi Chen; Yu Zhang; Yingkang Huang; Huilin Yang; Qin Shi
Journal:  J Orthop Translat       Date:  2019-04-28       Impact factor: 5.191

Review 7.  Exercise for osteoporosis: A literature review of pathology and mechanism.

Authors:  Lin Zhang; Yi-Li Zheng; Rui Wang; Xue-Qiang Wang; Hao Zhang
Journal:  Front Immunol       Date:  2022-09-09       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.